Pfizer (incl. Seagen)
Bought Seagen for $43B to become an ADC leader; also makes Ibrance, Lorbrena, Braftovi, and the first PROTAC.
Overview
Pfizer, based in New York and listed as PFE, bought Seagen for 43 billion dollars to become an antibody-drug conjugate leader, and it also makes Ibrance, Lorbrena and Braftovi and developed the first PROTAC, vepdegestrant, with Arvinas. The ADC portfolio covers Padcev, Adcetris, Tivdak, Tukysa, disitamab vedotin outside China and sigvotatug vedotin; the small-molecule side includes palbociclib, atirmociclib, lorlatinib, encorafenib and talazoparib; and a PD-1 by VEGF bispecific was licensed from 3SBio in 2025 with 1.25 billion dollars upfront. Nuclide links it to the EV-302, CROWN, BREAKWATER, ECHELON-1 and INO-VATE papers, to ponsegromab and cachexia as a treatable disease, to LIV-1 as a target and to Pfizer Ventures. Whether Seagen's platform yields new ADCs rather than only sustaining the acquired ones is the open question. Each product has its own page.
Scorecard
All companies- approved products +18
- modalities +4
- regions +6
- 24-month regulatory events +2
- registry trials +30
- Total revenue
- $63.6bn
- R&D spend
- $10.8bn
Dexrazoxane protects the heart from the cumulative damage of doxorubicin in women with metastatic breast cancer who need to keep receiving it, and, as Totect, limits tissue destruction when an anthracycline leaks out of a vein.
Enzalutamide is a second-generation androgen-receptor blocker that stops the receptor binding testosterone, entering the nucleus and switching on genes. It is approved at every stage of advanced prostate cancer, from rising PSA after surgery to castration-resistant disease, and fatigue, falls and memory problems are its main drawbacks.
Sunitinib is an anti-angiogenic pill approved for pancreatic neuroendocrine tumours, kidney cancer and GIST.
Similar pages
not linked directly; found by shared links- IndicationNon-metastatic castration-resistant prostate cancer
Shares PROSPER, Enzalutamide, Prostate cancer.
- IndicationMultiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)
Shares Sunitinib, Pheochromocytoma and paraganglioma (PPGL), Neuroendocrine tumours.
- CollectionUroToday
Shares Renal cell carcinoma, Prostate cancer.
- TrialA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta
Shares Renal cell carcinoma, Prostate cancer.
- TrialEMBARK
Shares Enzalutamide, Prostate cancer.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Enzalutamide, Prostate cancer.
- PathwayVHL / HIF oxygen sensing
Shares Pheochromocytoma and paraganglioma (PPGL), Renal cell carcinoma.
- TrialTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Shares Pheochromocytoma and paraganglioma (PPGL), Neuroendocrine tumours.